The companies will co-develop kits, which Trovagene will distribute globally, to analyze ctDNA from blood or urine using next-generation sequencing platforms.
The partners will offer pharmaceutical firms a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests.
The two companies said they will integrate their technologies to create a sample management and interpretation and reporting system.
China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
The planned solution will enable secondary and tertiary analysis and visualization of single-cell sequence data.
The company said its organic revenue growth during the quarter was 4 percent, and that acquisitions increased revenue by 3 percent.
As part of a development and global distribution agreement, the companies will develop and launch a kit directed towards mitigating a growing HAI-related concern.
Thermo Fisher will become the exclusive distributor for a technology to be developed with Boston-based Cytonome.
The assay will detect multiple classes of genomic alterations across a range of genes involved in homologous recombination repair.
The companies intend to bring companion diagnostics through US Food and Drug Administration clearance using ArcherDX's AMP chemistry and Illumina's MiSeqDx.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.